<DOC>
	<DOCNO>NCT00294762</DOCNO>
	<brief_summary>This first prospective study patient select basis two measure epidermal growth factor receptor ( EGFR ) pathway . The study ass prospectively efficacy erlotinib single agent intercalate chemotherapy highly select patient EGFR overexpression and/or EGFR amplification .</brief_summary>
	<brief_title>Erlotinib ( Tarceva ) Single Agent Intercalated With Combination Chemotherapy Patients With EGFR Positive NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Age &gt; = 18 Histologically cytologically document nonsmall cell lung cancer ( NSCLC ) Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 , 1 , 2 Radiologically measurable evaluable disease No prior chemotherapy 1 2 epithelial growth factor receptor ( EGFR ) pathway marker positive screen Tumor tissue block fine needle aspirate Any concurrent anticancer therapy radiation Other active malignancy Uncontrolled brain metastasis GI abnormality Severe abnormality cornea Significant cardiac disease Active infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>Tarceva</keyword>
	<keyword>Lung Cancer</keyword>
</DOC>